TCGA-CN-4737-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- ANGIOGENESIS+0.260
- UV_RESPONSE_DN+0.250
- HEDGEHOG_SIGNALING+0.230
- KRAS_SIGNALING_DN+0.230
- PANCREAS_BETA_CELLS+0.130
- TGF_BETA_SIGNALING+0.110
- ESTROGEN_RESPONSE_EARLY+0.080
- APICAL_JUNCTION+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.670
- E2F_TARGETS-0.610
- MYC_TARGETS_V1-0.610
- INTERFERON_GAMMA_RESPONSE-0.600
- OXIDATIVE_PHOSPHORYLATION-0.540
- G2M_CHECKPOINT-0.520
- MYC_TARGETS_V2-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.520
- MTORC1_SIGNALING-0.470
- ALLOGRAFT_REJECTION-0.450
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02165 | — | cohortA2 | 0.919 |
| 2 | TCGA-WA-A7H4-01A-21R-A34R-07 | — | — | 0.915 |
| 3 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.889 |
| 4 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.889 |
| 5 | SRR1313111 | — | A | 0.888 |
| 6 | AUR-AFUN-TTP1-A-1-0-R-A741-41 | — | D | 0.886 |
| 7 | SRR33346962 | — | — | 0.882 |
| 8 | 20030014.LumA | — | A | 0.880 |
| 9 | TCGA-BH-A0EI-01A-11R-A115-07 | — | B | 0.879 |
| 10 | d69e622a-6dee-48f3-bf06-7f6148d7472a | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.540 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |